Becton, Dickinson and Co. | BDX - Selling And Administration Expenses


Becton, Dickinson and Co. reported $1.21B in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Abbott USD 3.6B 330M Jun/2026
Agilent USD 465M 11M Mar/2026
Align Technology USD 462.67M 2.67M Jun/2026
AngioDynamics USD 36.57M 3.79M Sep/2025
Baxter International USD 735M 7M Jun/2026
Becton, Dickinson and Co. USD 1.21B 180M Mar/2026
Bio-Rad Laboratories USD 212.4M 8.6M Mar/2026
Boston Scientific USD 1.8B 22M Jun/2026
Cooper Companies USD 676.2M 303.1M Mar/2026
Danaher USD 2.07B 212M Jun/2026
Dentsply International USD 351M 32M Mar/2026
Dexcom USD 358.7M 9M Jun/2026
Edwards Lifesciences USD 561.2M 39M Jun/2026
Globus Medical USD 297.77M 20.7M Mar/2026
Insulet USD 317.2M 14.2M Mar/2026
Integra LifeSciences USD 166.22M 12.01M Jun/2026
Intuitive Surgical USD 617.9M 4.6M Jun/2026
J&J USD 6.42B 381M Jun/2026
Medtronic 2.96B 9M Dec/2025
Solventum Corp USD 783M 24M Mar/2026
Stryker USD 2.12B 32M Jun/2026
Tandem Diabetes Care USD 99.86M 5.34M Dec/2025
Teleflex USD 226.01M 3.64M Mar/2026
Terumo JPY 114.81B 9.55B Mar/2026
Thermo Fisher Scientific USD 1.91B 111M Jun/2026
Zimmer Biomet Holdings USD 849.9M 5.8M Mar/2026